Education
About Us
Working with TipRanks
Follow Us
AstraZeneca (AZN)
:AZN
AZN Stock Chart & Stats
$89.10
-$0.10(-0.15%)
At close: 4:00 PM EST
$89.10
-$0.10(-0.15%)
Day’s Range― - ―
52-Week Range$61.24 - $89.43
Previous CloseN/A
Volume1.80M
Average Volume (3M)5.08M
Market Cap
$275.92B
Enterprise Value$264.05B
Total Cash (Recent Filing)$8.18B
Total Debt (Recent Filing)$32.66B
Price to Earnings (P/E)29.4
Beta0.23
Next Earnings
Feb 05, 2026EPS Estimate
1.07Last Dividend Ex-Date
Aug 08, 2025Dividend Yield1.76%
Share Statistics
EPS (TTM)1.19
Shares Outstanding3,101,425,800
10 Day Avg. Volume4,913,892
30 Day Avg. Volume5,077,747
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)4.98
Price to Sales (P/S)3.76
P/FCF Ratio27.92
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue4.54
Enterprise Value/Gross Profit5.52
Enterprise Value/Ebitda14.72
Forecast
1Y Price Target
$94.00Price Target Upside5.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)4.59
Revenue Forecast (FY)$58.44B
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAZN presented full results from the Ph3 BaxHTN trial at the European Society of Cardiology meeting, showing significant reductions in systolic blood pressure for patients with uncontrolled or resistant hypertension.
Drug EfficacyBaxdrostat has a longer half-life than its competitor lorundrostat, allowing for 24-hour coverage and nocturnal blood pressure control.
Regulatory ApprovalPlans are in place to submit the trial data to regulators with a potential US launch, indicating confidence in regulatory approval and market success.
Bears Say
AstraZeneca News
AZN FAQ
What was AstraZeneca’s price range in the past 12 months?
AstraZeneca lowest stock price was $61.24 and its highest was $89.43 in the past 12 months.
What is AstraZeneca’s market cap?
AstraZeneca’s market cap is $275.92B.
When is AstraZeneca’s upcoming earnings report date?
AstraZeneca’s upcoming earnings report date is Feb 05, 2026 which is in 79 days.
How were AstraZeneca’s earnings last quarter?
AstraZeneca released its earnings results on Nov 06, 2025. The company reported $1.19 earnings per share for the quarter, the consensus estimate of $1.19 by $0.
Is AstraZeneca overvalued?
According to Wall Street analysts AstraZeneca’s price is currently Undervalued.
Does AstraZeneca pay dividends?
AstraZeneca pays a Semiannually dividend of $0.515 which represents an annual dividend yield of 1.76%. See more information on AstraZeneca dividends here
What is AstraZeneca’s EPS estimate?
AstraZeneca’s EPS estimate is 1.07.
How many shares outstanding does AstraZeneca have?
AstraZeneca has 3,101,425,800 shares outstanding.
What happened to AstraZeneca’s price movement after its last earnings report?
AstraZeneca reported an EPS of $1.19 in its last earnings report, expectations of $1.19. Following the earnings report the stock price went up 3.229%.
Which hedge fund is a major shareholder of AstraZeneca?
Currently, no hedge funds are holding shares in AZN
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$94.00 (5.50% Upside)
$94.00 (5.50% Upside)
Blogger Sentiment
Bullish
AZN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.85%
12-Months-Change
Fundamentals
Return on Equity
21.73%
Trailing 12-Months
Asset Growth
9.09%
Trailing 12-Months
Company Description
AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN Company Deck
AZN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong growth in revenue and successful pipeline developments, with significant achievements in the oncology segment and positive Phase III trial results. However, challenges persist in China and from Medicare Part D reform, with concerns about the loss of exclusivity for some products.View all AZN earnings summariesAZN Stock 12 Month Forecast
Average Price Target
$94.00
▲(5.50% Upside)
Technical Analysis
Ownership Overview
―
Insiders
5.44% Mutual Funds
3.27% Other Institutional Investors
90.30% Public Companies and Individual Investors